ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,611 | -21.2% | 124 | -24.8% | 0.00% | – |
| Q2 2023 | $14,726 | -33.0% | 165 | -19.5% | 0.00% | – |
| Q1 2023 | $21,980 | -94.2% | 205 | -95.0% | 0.00% | -100.0% |
| Q2 2022 | $380,000 | -20.8% | 4,093 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $480,000 | -12.9% | 4,093 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $551,000 | -15.5% | 4,093 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $652,000 | +21.2% | 4,093 | 0.0% | 0.00% | +33.3% |
| Q2 2021 | $538,000 | -13.6% | 4,093 | -15.4% | 0.00% | -25.0% |
| Q1 2021 | $623,000 | -22.8% | 4,837 | 0.0% | 0.00% | -20.0% |
| Q4 2020 | $807,000 | +29.1% | 4,837 | +19.4% | 0.01% | +25.0% |
| Q3 2020 | $625,000 | +4.3% | 4,052 | 0.0% | 0.00% | -20.0% |
| Q2 2020 | $599,000 | +90.8% | 4,052 | +45.5% | 0.01% | +66.7% |
| Q1 2020 | $314,000 | -18.9% | 2,785 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $387,000 | – | 2,785 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |